Enhabit (NYSE:EHAB) Issues Earnings Results

Enhabit (NYSE:EHAB) released its quarterly earnings results on Wednesday. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.03), Zacks reports. Enhabit had a positive return on equity of 1.67% and a negative net margin of 11.24%. Enhabit updated its FY 2025 guidance to 0.410-0.510 EPS.

Enhabit Stock Performance

Shares of NYSE EHAB traded up $0.08 during trading on Wednesday, hitting $8.55. The company had a trading volume of 306,020 shares, compared to its average volume of 276,512. The stock has a 50 day simple moving average of $8.16 and a 200 day simple moving average of $7.90. The firm has a market capitalization of $430.13 million, a P/E ratio of -3.69 and a beta of 1.83. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.46 and a current ratio of 1.46. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74.

Insider Activity at Enhabit

In other news, Director Jeffrey Bolton purchased 4,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $8.69 per share, for a total transaction of $34,760.00. Following the completion of the transaction, the director now directly owns 98,144 shares in the company, valued at $852,871.36. This trade represents a 4.25 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Stuart M. Mcguigan acquired 15,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average price of $8.81 per share, for a total transaction of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares in the company, valued at approximately $412,396.10. This trade represents a 47.15 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

EHAB has been the topic of a number of recent research reports. Leerink Partners reissued a “market perform” rating and issued a $8.00 target price (down previously from $8.50) on shares of Enhabit in a report on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and increased their price objective for the stock from $8.25 to $9.50 in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.75.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.